Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NU-0129 in recurrent glioblastoma or gliosarcoma
NCT03020017Phase 1Completed
- Sponsor
- Northwestern University
- Start
- May 2017
- Primary completion
- Sep 2018
- Modality
- Conjugated siRNA, Chemically Modified siRNA, Gold Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NU-0129 in glioblastoma multiforme (GBM) and Gliosarcoma (GS), sponsored by Northwestern University. Primary endpoint: Number of Patients With Adverse Events up to 21 days. Started May 2017; status: completed.
02
Drugs
NU-0129
03
Conditions
glioblastoma multiforme (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT03020017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03020017.